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bjectives Our aim was to assess the safety and feasibility of the retrograde trans-subclavian ap-
roach to transcatheter aortic valve implantation (TAVI) in selected high-risk patients with aortic ste-
osis (AS) and severe peripheral vasculopathy.
ackground TAVI is an emerging therapeutic option to treat inoperable/high-risk patients affected
y symptomatic AS. However, these patients are also often affected by severe iliac-femoral arteri-
pathy, rendering the transfemoral approach unemployable for percutaneous revalving procedure.
ethods From among those patients in our department between May 2007 and December 2008,
ho were refused surgical aortic valve replacement because of high surgical risk and were ineligible
or transfemoral percutaneous aortic valve replacement, we scheduled 3 for TAVI by the subclavian
pproach. Procedures were performed by a combined team of cardiologists, cardiac surgeons, and
nesthetists in the catheterization laboratory. The III generation CoreValve Revalving System (Core-
alve Inc., Irvine, California) with an 18-F delivery system was introduced in all cases by the left
ubclavian artery.
esults Prosthetic valves were successfully implanted in all 3 cases, leading to a fall in transvalvular
radient without signiﬁcant paravalvular regurgitation. No intraprocedural or periprocedural compli-
ations occurred. Two patients developed an atrioventricular block requiring the implantation of a
ermanent pacemaker. All patients were discharged in asymptomatic status, with good prosthesis
erformance. No adverse events occurred within the 3-month follow-up.
onclusions TAVI by subclavian retrograde approach seems safe and feasible in inoperable/high-risk
atients with AS and peripheral vasculopathy, who are neither eligible for surgical valve replacement nor
ransfemoral percutaneous aortic valve implantation. Further studies are needed to evaluate the long-
erm efﬁcacy of this new therapy. (J Am Coll Cardiol Intv 2009;2:828–33) © 2009 by the American
ollege of Cardiology Foundation
rom the Departments of *Interventional Cardiology and †Cardiac Surgery, Department of Cardiac, Thoracic, and Vascular Sciences,
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829ranscatheter aortic valve implantation (TAVI) has emerged
s a promising therapeutic option for treatment of inoperable/
igh-risk patients affected by symptomatic aortic stenosis (AS)
1–3). To date, about one-third of patients affected by AS are
ot considered for surgical valve replacement because of high
perative risk due to advanced age and multiple comorbidities
4), and their prognosis is poor (5). Percutaneous aortic valve
mplantation by a transfemoral retrograde approach has been
easible in the majority of these patients with a high procedural
uccess rate (6). However, limitations for percutaneous revalv-
ng therapy have been reported, mainly for anatomical reasons,
uch as inadequate annulus or aortic root size, unfavorable
ortic annulus/left ventricle (LV) outflow anatomy, and ob-
tructive disease of iliac-femoral arteries making them unsuit-
ble for large peripheral catheter access (7,8). Recently, a
ransapical approach has been proposed as an alternative
pproach to overcome this limitation in patients with unfavor-
ble peripheral anatomy (9). However this approach appears
emanding, since it requires a direct surgical exposure of
he LV apex and a multidisciplinary team in a dedicated
perating room. In selected patients, the trans-subclavian
pproach may be preferred because it is less invasive (2). We
eport on the safety and feasibility of retrograde trans-
ubclavian approach for TAVI in high-risk selected patients
ith AS and severe peripheral vasculopathy.
ethods
tudy population. Between May 2007 and December 2008,
1 patients affected by AS and referred to our department for
ortic valve replacement, were refused by surgeons because of
igh surgical risk and were considered for TAVI. Patient
creening included transthoracic echocardiogram, complete
ardiac catheterization, and coronary angiography, with an-
iography of iliac and femoral arteries. In particular, to deter-
ine annulus size, we used transthoracic echocardiogram; to
ssess the aortic arch angulation and ascending aorta dimen-
ions, we used aortic angiography. Inclusion and exclusion
riteria for treatment are reported elsewhere (6). Sixty-six
atients (72.5%) were shown to be eligible for TAVI using the
II generation CoreValve Revalving System (CoreValve Inc.,
rvine, California) by transfemoral approach. The causes of
xclusion were concomitant relevant mitral regurgitation (n 
), ascending aorta dilation (n  4), inadequate size of aortic
nnulus (n  2: 1 too large and 1 too small), aortic arch
ngulation (n  1), too frail (n  4), and hemorrhagic
iathesis (n 1). Finally, 5 patients were excluded because the
liac-femoral arteries were unsuitable for large sheath insertion
severe arteriopathy, small size, excessive tortuosity, or calcifi-
ation). To evaluate the feasibility of trans-subclavian access,
hese latter underwent computed tomographic scan of the
orta and supra-aortic vessels in order to assess the size, course,
nd calcification of the left subclavian artery, as well as aortic
rch and ascending aorta anatomy (Figs. 1A to 1D). One tatient was excluded from treatment because of severe calcifi-
ations and tortuosity of the subclavian artery; another one
ecause of diffuse narrowing of the subclavian artery with a
inimal lumen diameter less than 6 mm. By general agree-
ent, 3 of these patients, with a linear course of left subclavian
rtery and a minimal luminal diameter 6 mm, were sched-
led for transcatheter implantation of CoreValve by trans-
ubclavian retrograde approach. Patients and their relatives
onsented to the attempted implantation. Logistic Euro-
CORE (10) was calculated using the web-based system.
mplantation technique. The CoreValve Revalving System is
escribed elsewhere (2,6). Procedures were performed under
eneral anesthesia with double-lumen intubation in the cath-
terization laboratory by an operating team including 2 inter-
entional cardiologists, 2 cardiac surgeons, and 2 anesthetist
killed in transesophageal echocardiography. A 5-F sheath was
ercutaneously placed in the right radial artery through which
5-F graduate pigtail was advanced in the ascending aorta for
emodynamic monitoring and landmark aortic angiography. A
atheter for temporary pacing was advanced through the right
ephalic vein in the right ventricle. Cardiac surgeons performed
surgical cut-down to isolate the
eft subclavian artery just below
he subclavian bone (Figs. 2A and
B). A 7-F sheath was then intro-
uced into the subclavian artery
Figs. 2C and 2D) and, using a
eft Amplatz catheter, a straight
.035-inch guidewire was ad-
anced across the stenotic aortic
alve. The direct transvalvular
ortic gradient was measured.
hen, a super-stiff 260-cm long
ire (Amplatz Cook, Inc., Bloomington, Indiana) was intro-
uced into the LV, the Amplatz catheter removed, and the 7-F
heath replaced for an 18-F 30-cm long sheath (William Cook
urope, Bjaeverskov, Denmark) advanced into the ascending
orta (Fig. 2E). At this time, balloon aortic valvuloplasty was
erformed using a dedicated balloon (Numed Canada Inc.,
ornwall, Ontario, Canada) during rapid pacing. The Cor-
Valve Revalving System device was then carefully introduced
nd retrogradely advanced under fluoroscopic guidance over
he stiff wire in the ascending aorta across the aortic valvular
lane (Figs. 3A to 3C). After a careful check of valve position-
ng by angiography, the valve was progressively deployed (Figs.
D and 3E) and the delivery system retrieved. Immediately
fter TAVI, angiography of the ascending aorta was performed
o assess the presence, location, and degree of aortic regurgi-
ation and the patency of the coronary arteries, as well as to rule
ut complications, such as aortic dissection (Fig. 3F).
ransprosthesis pressure gradient was assessed by contempo-
ary pressure trace recording in the ascending aorta and LV.
eparin was administered to maintain an activated clotting
Abbreviations and
Acronyms
AS  aortic stenosis
LV  left
ventricle/ventricular
NYHA  New York Heart
Association
TAVI  transcatheter aortic
valve implantationime of 250 s throughout the procedure. Patients were
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830re-medicated with aspirin, clopidogrel, and vancomycin or
eicoplanin. After the procedure, the heparin was neutralized
y protamine, and the subclavian artery was restored by direct
uture. Thereafter, the subcutaneous and cutaneous tissues
ere also sutured (Fig. 2F). After the procedure, a dual
ntiplatelet regimen of aspirin 100 mg and clopidogrel 75 mg
aily for 6 months, after which 100 mg of aspirin daily was
rescribed indefinitely.
utcome. Procedural success was defined as technical success
ith a good performance of the bioprosthesis, and the patient
eaving the catheterization laboratory alive (6). Implantation
uccess was defined as adequate device positioning in the aortic
oot (6). Good performance of bioprosthesis was defined as a
eduction in mean transaortic gradient to less than 20 mm Hg
nd aortic regurgitation2, as evaluated by aortic angiogram
r echocardiogram (6). All events occurring within 30 days
rom the procedure were considered as procedure-related
vents (11). In particular, data regarding death and cardiovas-
ular death, neurologic event, myocardial infarction, ventricular
erforation, cardiac tamponade, aortic dissection, vascular ac-
ess complication, infections, and contrast induced nephropa-
Figure 1. Computed Tomographic Angiography of Left Subclavian Artery
Computed tomographic angiography performed in order to detect size, coursehy were collected. Echocardiography was performed at 24 to p8 h post-procedure, to assess prosthesis performance and LV
unction.
ollow-up. Clinical evaluation and transthoracic echocardiog-
aphy were performed at 1- and 3-month follow-ups.
esults
atient characteristics. The first patient was an 89-year-old
ymptomatic (New York Heart Association [NYHA] func-
ional class II) man with severe AS and LV dysfunction. He
as affected by arterial hypertension, chronic obstructive pul-
onary disease, and chronic kidney disease. Logistic Euro-
core was 53.84%; standard EuroScore was 14. He was judged
t high surgical risk because of a porcelain aorta. He was also
ffected by peripheral arteriopathy with multiple severe and
alcific stenosis of iliac-femoral arteries, not suitable for large
emoral sheath placement.
The second patient was an 83-year-old man affected by
evere symptomatic NYHA functional class III AS. He was
ffected by dyslipidemia, diabetes mellitus, chronic obstructive
ulmonary disease, and mild chronic kidney disease (logistic
uroScore 25.24%; standard EuroScore 11). He had had
calciﬁcation of left subclavian artery, aortic arch, and ascending aorta.revious cardiac surgery with 3 coronary artery bypass grafts, all
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831atent (left internal mammary on left anterior descending
rtery, venous jump graft on first diagonal branch, and obtuse
arginal branch). He had had subsequent percutaneous coro-
ary revascularization due to reinfarction. Thus, the patient
as refused by surgeons because of high surgical risk due to
revious cardiac reintervention and comorbidities; he was not
ligible for percutaneous aortic replacement by femoral ap-
roach because of severe calcification and tortuosity of iliac-
emoral arteries.
The third patient was a 78-year-old man with severe AS and
V dysfunction (low gradient–low flow AS). Comorbidities
ncluded hypertension, severe chronic obstructive pulmonary
isease, and renal failure. He had had coronary artery bypass
raft surgery 19 years before with venous grafts on the left
nterior descending artery and the left circumflex artery,
espectively. Four months before TAVI, he suffered from
on–ST-segment elevation myocardial infarction: a coronary
ngiogram showed patency of venous grafts for the left anterior
escending artery, chronic total occlusion of the right coronary
rtery with collateral circulation, occlusion of saphenous vein
raft for the left circumflex artery, and severe stenosis of the
btuse marginal branch. The patient was denied surgery
ecause of porcelain aorta and clinical conditions (logistic
uroScore 41.48%; standard EuroScore 13). At that time he
nderwent stenting of the obtuse marginal branch, and was
cheduled for TAVI. The transfemoral approach was not
uitable for multiple stenosis of iliac-femoral arteries.
rocedural results. The mean duration of the procedure was
Figure 2. Technical Steps of Left Subclavian Approach
After incision of cutaneous and subcutaneous tissues (A), a surgical cut-down
7-F sheath is introduced (D). After performing ascending aorta angiogram, cro
sheath is then exchanged for the larger 18-F long sheath (E). After revalving t
cutaneous tissues were sutured (F).6  40 min (range 67 to 142 min), with a mean fluoroscopy hime of 31  4 min and a mean contrast medium amount of
14  129 ml. Implantation success and procedural success
ere obtained in all 3 cases, leading to a significant reduction
n transvalvular gradient without significant para-prosthetic
eak. In 1 case, the good performance of bioprosthesis was
ained after post-deployment dilation performed to improve
rosthesis strut expansion and, as a consequence, to reduce
ara-prosthetic leak. All 3 patients were extubated within the
rst 2 h after the end of procedure. At 30 days from the
rocedure, no major adverse cardiac and cerebrovascular event,
o need for blood transfusion, infections, or contrast-induced
ephropathy occurred. The second and third patients devel-
ped complete atrioventricular block, 3 and 2 days after
mplantation, respectively, requiring permanent pacemaker
mplantation. In both cases, the implantation was planned and
erformed via right subclavian vein. Hospital stays were 6 days
or the first patient who did not need permanent pacemaker
mplantation, and 13 and 11 days for the other 2 patients,
espectively. Patients #1 and #3 were discharged with double
ntiplatelet therapy, while Patient #2 was scheduled to warfarin
lus clopidogrel therapy because of a pre-existing permanent
trial fibrillation. All patients were discharged in asymptomatic
tatus with good prosthesis function as assessed by echocardio-
raph examination.
ollow-up data. At 1 and 3 months follow-up, all patients were
live and experienced remarkable improvement in functional class.
wo patients improved to NYHA functional class I; 1 patient
mproved to NYHA class II (limited by severe lung disease). They
subclavian artery is performed (B). Then the artery is punctured (C) and a
the aortic valve and detecting transvalvular gradient, the previously placed
, the subclavian artery is restored by direct suture. Finally, subcutaneous andof left
ssing
herapyave returned to a normal life, limited only by their previous
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832edical conditions. No adverse events occurred. A good prosthe-
is performance persisted at 3-month follow-up in all patients.
iscussion
ecently, TAVI has emerged as alternative treatment for
egenerative AS in inoperable/high-risk surgical patients (1).
owever, the amount of patients eligible for transcatheter
reatment may be limited for anatomical reasons (6,7). In fact,
he size and geometry of aortic annulus, aortic root, and
scending aorta may be not suitable for adequate positioning of
he current available devices (8). Moreover, the presence of
eripheral artery disease may compromise the retrograde trans-
emoral arterial approach. The latter condition may be over-
ome by other transcatheter approaches, such as the antegrade
ransvenous or the transapical one.
The antegrade transvenous approach (1,12) appears more
uitable in introducing the large delivery systems reducing the
isk of vascular complications. However, trans-septal puncture
akes this approach very challenging, and special attention
ust be given at each step of the procedure not to damage
itral valve apparatus. For these reasons, this approach was
Figure 3. Aortic Revalving Therapy
The CoreValve Revalving System device was carefully introduced by the sheath
checking by angiography, the valve was released (D to E). Post-revalving asce
peri-prosthesis regurgitation and with patency of coronary ostia (F).ompletely rejected. sRecently, the transapical route was widely and successfully
erformed by using the Edwards-SAPIEN Valve (Edwards
ifeSciences Inc., Irvine, California) in patients with severe
eripheral vasculopathy (9,13). This approach allows the in-
roduction of delivery systems into the heart without limitation
n sheath diameter. However, it requires a hybrid operating
oom, a multidisciplinary team, and it is much more invasive.
oreover, transapical valve implantation has some technical
imitations, as in the case of severe septal hypertrophy in
ombination and with the angled position of the LV outflow
ract in relation to the aortic root (14).
In this scenario, a trans-subclavian retrograde approach
ould represent an intriguing alternative for TAVI in high-risk
ortic patients with associated severe iliac-femoral arteriopathy.
n fact, this approach combines the advantage of overcoming
eripheral vascular disease without the invasiveness of the
ransapical technique. As in the transapical approach, proce-
ural times are longer than in percutaneous transfemoral
mplantation, and a multidisciplinary team is needed. How-
ver, the trans-subclavian approach enables a more rapid
obilization of patients, and it seems reasonable that, in the
ear future, it will require only a local anesthetic and mild
advanced throughout the aorta into the aortic root (A to C). After careful
aorta angiogram demonstrates the correct positioning of the device, withoutand
ndingedation with further reduction in periprocedural times.
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833We experienced a simple surgical cut-down for the left
ubclavian artery, an easy insertion of the sheath with reliable
ositioning and release of the prosthesis in all attempted cases.
o intraprocedural or periprocedural complications occurred.
oreover, the trans-subclavian approach seems to provide a
ore direct access to the implantation site and an easier
elivery of the prosthesis than the transfemoral approach. In
act, in our experience, the manipulation of the device and the
ositioning of the valve are more precise and reliable by the
ubclavian approach, probably because of the shorter distance
rom the subclavian access to the aortic annulus requiring
eaker forces of tension and torsion, which bind the delivery
atheter.
One of our patients previously underwent coronary artery
ypass grafting with the left internal mammary artery. In cases
uch as these, the subclavian approach may be more challeng-
ng, and attention must be paid to introduce the sheath
arefully by fluoroscopic guidance. If the subclavian artery is
alcified and not too large, it might be safer to completely
ntroduce the sheath only to deliver the prosthesis into the
ortic arch, and then slightly retrieve the sheath itself in order
o minimize the risk of mammary flow obstruction and/or
issection. This caution should be adopted also in case of right
ertebral artery occlusion with a dominant left vertebral artery.
In our small series, patients did not experience vascular
omplications or cerebrovascular accidents. In fact, the prox-
mity of the subclavian access to the implantation site also
educes the likelihood of vascular complications when com-
ared with transfemoral access procedure. In addition, the
anipulation of the superstiff wire around a potentially calci-
ed aortic arch, which may cause particulate embolization and
ubsequent stroke, is more limited in the trans-subclavian
rocedure than in the transfemoral one.
Finally, in our experience, surgical wounds healed quickly in
pite of double antiplatelet therapy, and patients were dis-
harged within a short period, with good and stable hemody-
amic compensation, as assessed at a three-month follow-up.
onclusions
ranscatheter aortic valve replacement by subclavian retro-
rade approach seems safe and feasible in inoperable/high-risk
atients with AS and co-existing peripheral vasculopathy, who
re not eligible for surgical valve replacement or transfemoral
ercutaneous aortic valve implantation. This approach allowed
s to extend the current indications for TAVI and, together
ith a further reduction in delivery system caliber and the
evelopment of a new prosthesis, may increase the percentage
f eligibility for TAVI.
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